-
10:06:48 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

APLIF Stock News

04/27/22 7:37 AM
OTC : APLIF
conferences
Appili Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases, today announced that Stéphane Paquette, Vice President, Corporate Development, will present at the Bloom Burton& Co. Healthcare Investor Conference taking place on May 2 and 3, 2022.. Date: Tuesday, May 3, 2022 Time: 3:00 pm ET Location: Metro Toronto...
RHEA-AI
neutral
03/29/22 7:36 AM
OTC : APLIF
Appili Therapeutics Announces Non-Convertible Secured Loan of US$3.6 Million and License and Distribution Agreement with Long Zone Holdings
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases, today announced that it has entered into a senior secured loan and exclusive license and distribution agreement with Long Zone Holdings Inc., led by Jonathan Ross Goodman, founder of both Paladin Labs Inc. and Knight Therapeutics Inc..
RHEA-AI
positive
02/28/22 7:40 AM
OTC : APLIF
Appili Therapeutics Announces Over US$10 Million in New Funding from US Department of Defense for Biodefense Vaccine Candidate ATI-1701
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases, today announced that the U.S. Department of Defense, via the Joint Science and Technology Office of the Defense Threat Reduction Agency, has selected for funding an Appili proposal that would provide over US $10 million to advance the Company’ s...
RHEA-AI
neutral
02/14/22 5:10 PM
OTC : APLIF
earnings
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2022
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases, today announced its financial and operational results for the third quarter of its fiscal year 2022, which ended on December 31, 2021. “Over the past few months, we made meaningful progress fortifying partnerships to accelerate and expand our...
RHEA-AI
neutral
02/08/22 7:17 AM
OTC : APLIF
partnership
Appili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis Pharmaceuticals
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases, announced today it has amended its agreement with Saptalis Pharmaceuticals LLC, a New York- based specialty pharmaceuticals company, to expand the territories in which Saptalis will commercialize ATI-1501, Appili’ s liquid oral reformulation of...
RHEA-AI
neutral
11/19/21 7:42 AM
OTC : APLIF
managementclinical trial
Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Study Evaluating Biodefense Vaccine Candidate ATI-1701 and Change to Board of Directors
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases, today announced positive one year challenge results from its preclinical study evaluating the efficacy of biodefense vaccine candidate ATI-1701 in a lethal model of tularemia. Both 28- and 90- day efficacy data have also been presented...
RHEA-AI
neutral
11/12/21 5:41 PM
OTC : APLIF
earnings
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2022 and Change of Chief Financial Officer
Appili Therapeutics Inc., a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the second quarter of its fiscal year 2022, which ended on September 30, 2021. “Although the top-line results of our Phase 3 PRESECO trial were not what we had hoped for, I am incredibly proud of all that...
RHEA-AI
neutral
11/12/21 7:19 AM
OTC : APLIF
clinical trial
Appili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan®/Reeqonus™
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases, today announced that the Phase 3 PRESECO clinical trial evaluating oral antiviral Avigan ®/ Reeqonus™ for the treatment of mild-to-moderate COVID-19 did not achieve statistical significance on the primary endpoint of time to sustained clinical...
RHEA-AI
neutral